• Qianyu Zhang, Meiling Liu, Yunchao Zhong, and Kang Zhang.
• Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
• Medicine (Baltimore). 2022 Jan 14; 101 (2): e28583e28583.

RationaleThis is the first known report to describe a case of advanced non-smoking lung adenocarcinoma with no epidermal growth factor receptor mutation after comprehensive epidermal growth factor receptor-tyrosine kinase inhibitor-based therapy that survived for nearly 12 years.Patient ConcernsA 48-year-old Chinese woman that came to our hospital with a left supraclavicular mass.DiagnosisThe final diagnosis was left lung adenocarcinoma with left supraclavicular lymph node metastasis, cT1N3M0 IIIB (International association for the Study of lung cancer 6th version).InterventionsAfter 4 months of 4 cycles of chemotherapy, gefitinib was administered alone for 5.5 years. Local radiotherapy (40GY/20F) was administered for 1 month, and osimertinib alone was followed for 4.5 years. A combination of pemetrexed with oxaliplatin and hyperthermia at the same time was administered for 4 cycles. Toripalimab and anlotinib were administered for 3 months. Since then, the patient had been taking a double dose of icotinib herself.OutcomesThe patient has survived for nearly 12 years since diagnosis of lung cancer.LessonsOur case is of significant importance to clinicians involved in the treatment of patients with advanced nonsmoking lung adenocarcinoma and no epidermal growth factor receptor mutations.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

28 keywords...

hide…